### The Turnaround Driven by Pricing Power
Colgate-Palmolive India's third quarter of fiscal year 2026 saw a reversal in its revenue trajectory, with top-line figures climbing 2% year-on-year to INR 14.9 billion, a figure aligning with analyst expectations [cite: Source A, 8]. This growth signals an end to a three-quarter period of contraction. However, the underlying engine for this revenue expansion was not increased sales volume. Toothpaste volumes experienced a contraction of around 2%, a continuation of softness in core product demand [cite: Source A, 3]. The company's ability to implement price hikes effectively compensated for this volume shortfall, a strategy that stands in stark contrast to competitors like Dabur India, whose toothpaste segment posted a more robust 10% growth [cite: Source A]. Analysts at Motilal Oswal noted that while the revenue met estimates, the volume pressure highlights persistent challenges in the mass-market portfolio, even as premium segments show resilience.
### Competitive Pressure and Valuation Disconnect
The broader Indian FMCG sector is navigating a complex environment. For 2026, industry projections anticipate a shift towards volume-led growth, supported by easing inflation and anticipated GST benefits. However, Colgate's recent performance suggests it is not fully capturing this nascent volume recovery. Dabur India, a key competitor, reported a 6.1% revenue increase for Q3 FY26, with its toothpaste business growing approximately 10% and its overall India FMCG business seeing a 6% rise, underscoring a strong competitive push. Dabur's strategy appears to be succeeding in market share gains across categories, including hair oils and juices.
Colgate's stock has seen a significant correction, declining approximately 25% over the preceding 12 months [cite: Source A, 7]. This price action has brought its valuation into focus. The stock trades at forward P/E multiples of 38x and 35x for FY27 and FY28, respectively, according to Motilal Oswal [cite: Source A]. While these figures might appear 'comfortable' in some analyses, broader market data places its trailing P/E ratio around 43.32x as of late January 2026. This valuation is considered 'Very Expensive' by some, despite the company's exceptional Return on Equity (ROE) of over 73%, which is notably high among FMCG peers. This disconnect between premium valuation and tepid volume growth is a key point of investor scrutiny, questioning the sustainability of profitability without broader top-line momentum.
### Analyst Confidence Amidst Headwinds
Despite the volume pressures and competitive headwinds, Motilal Oswal reiterates its 'BUY' recommendation for Colgate-Palmolive India. The brokerage has set a price target of INR 2,450, based on a 40x P/E multiple for December 2027 [cite: Source A]. This target suggests an implied upside from current trading levels, which were hovering around INR 2,090-2,110 in early February 2026. The rationale likely hinges on the company's proven ability to manage margins, a strong brand legacy, and the expectation that broader FMCG sector recovery will eventually translate to volume gains for Colgate. The company also recently filed its standard quarterly results, with no significant regulatory red flags emerging. The market consensus appears to be weighing the company's operational resilience and strong balance sheet against its anemic volume growth in the near term.